Astrazeneca PLC stock price, AZN

Astrazeneca PLC stock chart:



Astrazeneca PLC close price: 34

Stock price forecast:

DOWN TO -0.82%
Target: 33.72

Total forecasts: 60
Reached: 5 (8.33%)

Total Win: 0.89 (2.91%)

DaysForecastsReached%Reached points%InvestedUnreached%Total%
No results found.

Showing 1-10 of 523 items.
Date of ForecastStock PriceTarget PriceForecast Reached Date
2017-06-263433.720000-00-00
2017-06-253433.710000-00-00
2017-06-243433.710000-00-00
2017-06-233433.70000-00-00
2017-06-223433.710000-00-00
2017-06-213433.710000-00-00
2017-06-203433.670000-00-00
2017-06-193433.630000-00-00
2017-06-183433.660000-00-00
2017-06-173433.650000-00-00

Astrazeneca PLC latest news:


  • 06/19/2017 10:26:37

    GSK's new pharma head to join in September after AstraZeneca tussle

    LONDON (Reuters) - GlaxoSmithKline has struck a deal for Luke Miels to start as its new head of pharmaceuticals in September, following a lengthy dispute over his contract with his former employer AstraZeneca.

  • 05/12/2017 10:03:06

    FTSE 100 boosted by AstraZeneca rise

    Shares in the pharmaceutical giant are boosted by promising results from a drug trial.

  • 05/12/2017 01:54:47

    Drug trial results lift AstraZeneca shares

    Shares in the pharmaceutical giant climb, boosting the FTSE 100 in early trade.

  • 05/03/2017 09:25:33

    Pieris Pharma Soars on AstraZeneca Collaboration


  • 05/03/2017 06:14:21

    Pieris Pharma stock soars 54% on news of $57.5 mln AstraZeneca deal

    Pieris Pharmaceuticals Inc. shares surged as much as 54% in premarket trade Wednesday on news of the company's $57.5 million deal with AstraZeneca to develop drugs for respiratory diseases. The deal includes $45 million upfront and $12.5 million in a milestone payment once Pieris begins a phase 1 trial this year for its lead preclinical drug, PRS-060, which is intended for patients with moderate to severe asthma. AstraZeneca will fund all clinical development and commercialization for PRS-060, with Pieris having the option of U.S. co-development and co-commercialization starting in phase 2a clinical trials. The agreement covers four additional therapeutic programs, with Pieris having the option for U.S. co-development and co-commercialization for two of them. Pieris is eligible for up to $2.1 billion in development dependent milestone payments and eventual commercial payments, according to the release. Pieris shares have surged 11.1% over the last three months, compared with a 4.1% rise in the S&P 500 . Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 04/27/2017 01:43:21

    UPDATE 1-AstraZeneca hopes to escape drug sales trough in second half

    * Focus on pivotal lung cancer trial results due mid-year (Adds analyst comment, shares, detail on competitors)

  • 04/27/2017 01:08:27

    AstraZeneca Q1 upbeat on cancer drugs despite Q1 sales drop

    Anglo-Swedish drugmaker AstraZeneca says first-quarter revenue fell amid declining sales of cholesterol treatment Crestor, which lost patent protection last year

  • More trends:

    AT&T Inc.T | Atento S.A.ATTO | Atlantic Power CorporationAT | Atlas EnergyATLS | Atlas Resource PartnersARP | Atlas Resource PartnersARP^D | Atlas Resource PartnersARP^E | Atmos Energy CorporationATO | Atwood OceanicsATW | AU Optronics CorpAUO |